Last year,GlaxoSmithKline(LSE :GSK) and peerNovartisunveiled acomplex three-waydeal inwhichthe twopharmaceuticalgiants wouldtrade more than 11bn of assets.
The innovative deal is designed to help the two groups clean uptheir asset portfolios. Glaxo is offloading its cancer treatment division to gain Novartis vaccine units and also enter into a joint venture to create the worlds biggest consumer healthcare business.
The deal is set to boost Glaxos sales by 1.3bn,to 26.9bn, on a 2013 pro forma basis and is also expected tobe accretive to core earnings per share from the first year. Further benefits are expected to filter through until 2017as the delivery of cost savings, new product launches and the re-introduction of Novartis over the counter products accelerates.
Additionally, Glaxoestimates that total annual cost savings of 1bn could be achievable by the fifth full year following closing.
And so far, this complex three-way deal is going to plan.Regulators in both the US and Europe have given the green light and the two companies are on-track to close the sometime in the next five months.
Missing something
All in all, the Glaxo-Novartis deal will be extremely beneficial to Glaxos earnings over the long term. Cost savings of 1bn per annum will also widen the groups profit margins, boosting profit for shareholders and giving more room for dividend payouts as well as stock buybacks.
But investors are also set to profit in the short term. You see, theres one key paragraph in the Glaxo-Novartis deal document that many investors seem to have missed:
Capital return
GSK plans to use net after tax cash proceeds of $7.8 billion to fund a capital return of 4 billion to shareholders following completion of the transaction. This return is expected to be implemented through a B share scheme in 2015, subject to approvals. Specific details related to the execution of the B share scheme will be sent to shareholders in due course.
With around 5bn shares outstanding, a cash return of 4bn is worth around 80p per share. In other words, Glaxos investors are set to receive a special dividend of 80p per share this year. This is excluding the companys regular, quarterly dividend payout which is also set to total 80p per share for the year.
Set to outperform
So overall, Glaxos shareholders could beset to receive dividend income of 160p per share this year, a yield of 11% at current prices. This hefty yield should help Glaxo outperform during 2015 and most investors will be looking to reinvest the payout which should push the companys shares higher.
But if Glaxo’s yield of 11% isn’t enough and you’re still looking for dividend opportunities, then the Motley Fool is here to help. Our top analysts have put together thisnewfree reporttitled”How To Create Dividends For Life“which is designed to help you discover the market’s best income stocks.
What’s more, for a limited time onlyyou can gettwo reports in one. Along with “How To Create Dividends For Life”, we’re throwing in a new report entitled “My 5 Golden Rules for Building a Dividend Portfolio”.
Justclick hereto download the free report double pack today!
Get FREE Issues of The Motley Fool Collective
Get straightforward advice on whats really happening with the stock markets, direct to your inbox. Help yourself with our FREE email newsletter designed to help you protect and grow your portfolio wealth.
By providing your email address, you consent to receiving further information on our goods and services and those of our business partners. To opt-out of receiving this information click here. All information provided is governed by our Privacy Statement.
Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
